Secondary Logo

Share this article on:

American Urogynecologic Society Best-Practice Statement: Recurrent Urinary Tract Infection in Adult Women

Brubaker, Linda, MD*; Carberry, Cassandra, MD*†; Nardos, Rahel, MD; Carter-Brooks, Charelle, MD§; Lowder, Jerry L., MD

Female Pelvic Medicine & Reconstructive Surgery: September/October 2018 - Volume 24 - Issue 5 - p 321–335
doi: 10.1097/SPV.0000000000000550
AUGS Guidelines

From the *Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Reproductive Medicine, University of California San Diego, San Diego, CA;

Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, RI;

Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Oregon Health & Sciences University, Portland, OR;

§Division of Urogynecology and Reconstructive Surgery, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA; and

Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Washington University in St Louis, St Louis, MO.

Reprints: Linda Brubaker, MD, University of California San Diego, 9500 Gilman Drive, MC 0971, La Jolla, CA 92093. E-mail: librubaker@ucsd.edu.

Disclosures: Brubaker has received editorial stipends (Female Pelvic Medicine and Reconstructive Surgery, Up to Date). The remaining authors have no disclosures to report.

Linda Brubaker, MD, and Cassandra Carberry, MD, are co–first authors.

This document was developed by the American Urogynecologic Society Guidelines and Statements Committee with the assistance of Linda Brubaker, Cassandra Carberry, Rahel Nardos, Charelle Carter-Brooks, and Jerry Lowder. This peer-reviewed document reflects clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed.

All Writing Group members disclosed commercial and financial relationships. Writing Group members who were found to have conflicts of interest based on the relationships disclosed did not participate in the final approval of this document.

Executive Summary—Best practices in the care of women with rUTI:

Make the rUTI Diagnosis:

UTI, culture-documented episodes (≥2 in 6 months or ≥3 in 12 months).

Urine Testing:

Avoid dipstick as sole test

Use UA if knowledge of pyuria alters your care

Avoid reflex urine culture

Interpret pretreatment urine culture and sensitivities with knowledge of local resistance patterns; consider posttreatment urine culture

Code Correctly: See Table 1.

Treat Optimally: Use nitrofurantoin, TMP-SMX or fosfomycin as first-line agents whenever possible.

Reduce Recurrence Risk: Based on specific clinical factors for affected woman.

Nonantibiotic strategies:

Vaginal estrogen in hypoestrogenic women without contraindication. Consider methenamine.

Prophylactic antibiotic regimens (ensure negative urine culture before initiating prophylaxis):

Postcoital low-dose antibiotic, if coitally associated episodes.

Judicious use of daily, low-dose oral antibiotic.

Female pelvic medicine and reconstructive surgery (FPMRS) specialists provide care for women with recurrent urinary tract infection (rUTI). In a study of more than 1100 urogynecologic patients, investigators reported a patient-reported rUTI prevalence of 19%.1 However, clinical care varies because of a lack of evidence and best practices. In addition, variable rUTI definitions exacerbate the gap in our understanding of this common clinical problem. In the context of evolving evidence and reviews on rUTI, this document summarizes current best practice for rUTI diagnosis and management in women. These best practices do not apply to women who are pregnant, are immunosuppressed, have surgically altered urinary tracts (not including typical surgery for stress urinary incontinence or pelvic organ prolapse), or regularly use urinary catheters except where specified. In addition, this document does not cover diagnosis or treatment of asymptomatic bacteriuria.

Back to Top | Article Outline

Terminology and Definitions

A commonly used definition describes urinary tract infection (UTI) as an infection of the lower and/or upper genitourinary tract which is diagnosed based on the presence of a pathogen in the urinary tract and associated symptoms.2 This definition assumes that the symptoms are caused by the detected uropathogens. However, neither the uropathogen detection method nor any specific symptoms are inherent in this UTI definition. Although the umbrella term UTI formally includes both upper and lower urinary tracts, the term UTI is often used interchangeably with cystitis (more accurately bacterial cystitis). There is limited evidence to support any “gold standard” UTI definition for epidemiologic or clinical research.

There are multiple definitions for rUTI. This best-practice statement endorses a clinically useful, culture-based definition: at least 2 culture-proven episodes in 6 months, or at least 3 in 1 year.3 It is assumed that these episodes are separate events; however, there is no consensus as to diagnostic requirements to document resolution of any episode, such as a posttreatment culture. Diagnosis and care of rUTI patients does not require use of the various terms proposed to further subtype frequent UTI, although the presence of persistent organisms may alter the diagnostic and/or treatment approach (eg, earlier search for foreign body or urinary stone). Relapse indicates that the same uropathogen causes UTI symptoms within 2 weeks of completing appropriate antibiotic therapy. Recurrence specifically applies to situations in which there is evidence that the subsequent UTI occurred beyond the initial 2 weeks or with a different uropathogen.4

Back to Top | Article Outline

Epidemiology

Estimates of UTI incidence vary based on the research definition of UTI being used and the likely overuse of UTI codes before a completed diagnostic evaluation. Commonly cited references suggest that more than 8 million ambulatory visits (84% women) in the United States in 2007 were due to UTI; 21% were emergency department visits.5,6 Using a woman's report of a physician diagnosis of UTI, the National Health and Nutrition Examination Survey data reported a 12.6% annual incidence of UTI in women 18 years or older.7 In a mixed-sex population of more than 30,000 patients whose UTI diagnosis had urine culture confirmation, Canadian investigators reported the annual UTI incidence in women aged 20 to 79 years as 3% to 5% and those aged 80 to 89 years as 12%. Two percent of these women had at least 6 UTIs in 2 years.8

After a single UTI, 30% to 44% of women will have a recurrent UTI; 50% will have a third episode if they have had 2 UTIs in 6 months.3 In a study of college women with a UTI, 19% experienced recurrence within 6 months.9 In a recent study, Suskind et al,10 using a database of health care claims, studied women aged 18 to 64 years who had an evaluation and management visit associated with an International Classification of Disease, Ninth Revision code for UTI and an antibiotic prescription within 14 days of that visit. They reported an overall rate of incident rUTI cases of 102 per 100,000 women per year, with the highest rates in women 18 to 34 years old and 55 to 66 years old.

Back to Top | Article Outline

Pathophysiology

Adjacent pelvic microbial niches serve as reservoirs for uropathogens that can lead to UTI/rUTI.11 Currently, the majority of evidence for uropathogens in the urine comes from standard urine culture techniques, which have been refined to detect Escherichia coli. Standard cultures also detect other common pathogens including Klebsiella species, Staphylococcus saprophyticus, Enterococcus faecalis, and Streptococcus agalactiae. Culture-independent techniques, such as polymerase chain reaction testing and sequencing, confirm that standard urine cultures do not detect all uropathogens or other resident microbes of the urinary microbiota.11 Enhanced culture techniques complement culture-independent methods to advance our understanding of UTI and rUTI prevention, pathogenesis, treatment, and recovery but are not yet widely available for clinical use.

Current evidence, based on standard cultures, indicates that E. coli causes most (70%–95%) community-acquired UTIs. Studies in older women suggest that E. coli accounts for more than half of UTIs, whereas other common organisms are Klebsiella pneumoniae, Proteus mirabilis, and E. faecalis. E. coli is also the most common cause of rUTI (66%). The uropathogens associated with rUTI are the same microbes associated with episodic (non-rUTI) UTI episodes. However, non–E. coli pathogens and resistant organisms are more likely to be associated with UTI episodes in women with rUTI.3,7,12

E. coli has multiple strains and virulence factors.13 Uropathogenic E. coli (UPEC) has been widely studied in murine models, and some findings have been verified in human studies.14,15 Uropathogenic E. coli have special features that facilitate urothelial attachment, allowing the microbe to take up residence within the bladder.14,15 Uropathogenic E. coli can form intracellular bacterial communities that act like a biofilm, allowing bacteria to persist in quiescent intracellular reservoirs, acting as a source of recurrent infection.16,17 Episodes of rUTIs are often associated with the same bacterial strain; this has important implications for treatment, highlighting the need for careful antimicrobial sensitivity testing and treatment selection.

In addition to bacterial factors, host factors, including hormonal status, anatomy, functional, and behavioral variables, and genetic factors likely modulate UTI and rUTI susceptibility.3,14,18 For example, E. coli has an increased ability to adhere to the urothelium in women who are nonsecretors of certain blood group antigens.3,19 Individual factors, such as pre-UTI microbiota/microbiome health, degree of inflammation, and urothelial exfoliation from an infection, may affect response to UTI, recovery from UTI, and susceptibility to future UTI.13,14

Back to Top | Article Outline

Risk Factors

Many commonly recommended behaviors have not been established as reducing risk for rUTI (wiping away from the urethra; voiding before and after intercourse; increasing frequency of voiding; wearing certain types of underwear; avoiding douching; or avoiding hot tubs, bubble bath, or tampons).3 Physicians should consider the contribution of gross fecal soilage, as in women with fecal incontinence.

A personal history of UTI before age 15 years and maternal UTI history are rUTI risk factors.3,20 A case-control study of more than 400 women reported an increased risk of rUTIs in women having a first-degree female relatives with a history of at least 5 UTIs.21 Sexual risk factors, such as a new sexual partner, intercourse frequency, and spermicide use, are more common in premenopausal women.21

Women with pelvic floor disorders are at increased risk for rUTIs, especially postmenopausal women with urinary incontinence. Some investigators suggest an association between postvoid residual of at leasy 50 mL and rUTI.19 The association with prolapse is unclear.22

There is a risk of rUTI after surgery for stress urinary incontinence. The early postoperative period is associated with a transient increased rUTI risk (11%) after retropubic tension-free vaginal tape with or without concomitant prolapse repair.23 Beyond the first 6 postoperative weeks, investigators reported rUTI in 2.3% to 2.4% of participants in 2 randomized surgical trials (Stress Incontinence Surgical Treatment Efficacy trial and Trial of Mid-Urethral Slings).24 Between 2 and 12 months, women who had a midurethral sling had a postoperative rUTI rate of 2.3%.25 No cases of rUTI were reported during a recent 10-year follow-up of 71 women who had transobturator midurethral slings.26

Back to Top | Article Outline

DIAGNOSIS

Women with frequent UTI may experience diagnostic delay if clinicians do not review the UTI history; clinicians should order pretreatment urine cultures to document rUTI (culture-proven UTI ≥2 in 6 months or ≥3 in 12 months).3 Although infrequent UTI can be assessed with less rigor and treated empirically, women with frequent UTI who are being formally assessed for rUTI should have detailed symptom assessment and pretreatment urine culture and sensitivity.4

Back to Top | Article Outline

Symptoms

Dysuria is a key symptom of bacterial cystitis. Frequency, urgency, hematuria, and suprapubic pain are variably present. Symptoms of flank pain, fever and chills, and nausea and vomiting should prompt consideration of pyelonephritis. In young women, there is a 90% probability of a UTI when she reports dysuria and frequency in the absence of vaginal discharge or irritation.6 The accuracy of history and physical examination for UTI diagnosis in women suggests an increased UTI probability with dysuria (likelihood ratio [LR], 1.5; 95% confidence interval [CI], 1.2–2), frequency (LR, 1.8; 95% CI, 1.3–3), hematuria (LR, 2.0; 95% CI, 1.3–2.9), back pain (LR, 1.6; 95% CI, 1.2–2.1), and costovertebral angle tenderness (LR, 1.7; 95% CI, 1.1–2.5). The probability of UTI diagnosis is reduced with a history of vaginal discharge (LR, 0.3; 95% CI, 0.1–0.9) or vaginal irritation (LR, 0.2; 95% CI, 0.1–0.9).27

With aging, symptoms potentially associated with a UTI may be less clear. Acute dysuria remains a reliable symptom, new-onset frequency or urgency has been found to correlate with UTI, and new-onset urinary incontinence should prompt evaluation for UTI.28,29 Nontraditional symptoms, such as urinary odor or urinary appearance, may be triggers for urogynecologic patients to seek care for presumed UTI.2,3,30 Women with cognitive limitations may have difficulty reporting symptoms; family/caregivers may alert health care providers to changes in mentation or energy levels, which may indicate UTI, although this is a diagnostic challenge.2 Despite the common clinical observation, worsening of chronic incontinence or other urinary symptoms are not reliably associated with UTI.2,31

There is significant symptom overlap between UTI and many urogynecologic conditions, including urgency urinary incontinence, overactive bladder, and bladder pain syndrome. Currently, our understanding of appropriate symptom attribution in this patient population is lacking.

Back to Top | Article Outline

Urine Dipstick

The urine dipstick has value to rule out, rather than rule in, UTI in patients with lower pretest probably of UTI. Because women with rUTI do not have a low pretest probability of UTI, dipstick testing is not advised and pretreatment urine culture is necessary.

Back to Top | Article Outline

Urinalysis

Beyond the standard indications for testing (hematuria, proteinuria, etc), urinalysis in women with rUTI can confirm pyuria (at least 10 white blood cells per high-power field). The interpretation of pyuria for women with rUTI remains debatable because of a lack of relevant studies in urogynecologic populations. When the finding of pyuria would alter the treatment plan, the clinician should obtain a urinalysis.

Back to Top | Article Outline

Urine Culture

The criteria for UTI diagnosis by urine culture varies and has not been validated in any urogynecologic population. The standard urine culture along with microscopic urinalysis has been used as a criterion standard for confirming suspected UTI. A positive culture is typically characterized by bacteriuria of at least 105 colony-forming unit s (CFU)/mL,32 although according to the European Association of Urology guidelines, a count of 103 CFU/mL in symptomatic patients is sufficient for diagnosis.33 The Society of Obstetricians and Gynaecologists of Canada clinical practice guidelines state that even 102 CFU is sufficient in the setting of UTI symptoms.32 Clinicians should have a clear understanding of their clinical laboratory protocols as certain laboratories may report 104 or less as “no growth.”

Best practices for posttreatment test of cure (test-treatment-test) urine culture vary and are based on expert opinion. Reliance on symptomatic resolution alone forgoes the ability to detect patterns of uropathogen persistence or recurrence.20 The Canadian Urological Association guidelines suggest repeating a urine culture 1 to 2 weeks after treatment to test for persistence.4 A repeat urine culture may allow for detection of patterns of uropathogen persistence or recurrence that may provide insight into the etiology or optimal treatment.20 A negative posttreatment urine culture provides evidence of effective treatment. In the absence of a negative posttreatment urine culture, it is possible that 2 or 3 UTI episodes are related to a single persistent uropathogen.

However, clinicians face a dilemma when the posttreatment culture is positive and the patient's UTI symptoms have resolved. Some experts who believe that women with an active diagnosis of rUTI can also carry a diagnosis of asymptomatic bacteriuria recommend against posttreatment testing to reduce the risk of treating asymptomatic bacteriuria and lessen antibiotic exposure.2,3,34 Young women with asymptomatic bacteriuria participating in a randomized trial who were treated were (1) more likely to develop subsequent infections at a higher rate than those who were not treated and (2) more likely to develop antibiotic-resistant organisms.34,35

Back to Top | Article Outline

Physical Examination

Although a physical examination may not be necessary before treatment for a woman with infrequent UTI, an examination should always occur as part of the rUTI evaluation to detect an underlying etiology, potential contributors (hypoestrogenism), and findings suggestive of upper tract involvement. In addition to an assessment of the patient's general status, focused examination should include palpation for costovertebral angle and suprapubic tenderness. The pelvic examination, including bimanual, can check for vulvar skin and/or architecture changes, urethral diverticulum, tenderness in pelvic floor muscles, urethra or bladder, vaginal discharge, and pelvic masses. In addition, detection of pelvic organ prolapse, presence of a foreign body such as a retained pessary, or eroded mesh or sutures will inform the treatment plan. These assessments should be performed with initial evaluation of a patient with rUTI and repeated as needed depending on status changes, including new signs, symptoms, or risk factors.

Back to Top | Article Outline

Additional Testing

Postvoid Residual

A postvoid residual should be measured to ensure that there is no significant urinary retention. This can be done at the time of the physical examination.

Back to Top | Article Outline
Imaging and Endoscopy

There are currently no specific guidelines for imaging studies for women with rUTI. Indications for imaging in women with UTI include persistent symptoms (persistent fever after 72 hours of appropriate antibiotic therapy), rapid recurrence after appropriate treatment, suspected stone or obstruction, and women with diabetes who are at higher risk for complications such as abscess, emphysematous pyelonephritis, and so on.35,36 Cystourethroscopy should be considered if a woman is at risk for suspected foreign body within the bladder or urethra, although the utility of cystoscopy in evaluation of rUTI has not been well studied. One retrospective study reported that 3.8% of the 163 participants had specific findings on cystoscopy that imaging would not detect.37 Cystoscopy with cytology should be performed when there is clinical suspicion for premalignancy or malignancy. Assessment for urinary tract stones can be initiated with plain abdominal radiographs. When the clinical situation warrants more complete assessment of the upper tracts, renal ultrasound, or computed tomographic urography should be used. In general, a computed tomographic urogram, which is with and without intravenous contrast, is the imaging modality of choice in patients suspected of having pyelonephritis, and renal and perirenal abscess. This modality can also identify a possible source of infection such as renal or ureteric stones.38

Back to Top | Article Outline

Coding and Documentation

Women who meet the criteria for rUTI should have this diagnosis added to their problem list to help alert other providers to the recurrent nature of the UTIs and to help ensure that best practices are followed for evaluation and treatment. In addition, methods to track UTIs (date, pathogen, antibiotic prescribed) can be developed in summary or flowsheets in the medical record.

Accurate use of International Classification of Disease, 10th Revision, Clinical Modification (ICD-10-CM) is important for correct classification of patients for clinical diagnosis and population studies of rUTI. Table 1 describes many of the ICD-10 codes associated with lower UTI. The ICD-10 code of “positive urine culture” can be used instead of UTI or asymptomatic bacteriuria when a urine culture is positive but the clinical criteria are not met for a UTI: for example, if a patient is asymptomatic and a culture is inadvertently obtained before treatment completion or while the patient is on suppression but asymptomatic. We propose providers replace the active rUTI diagnosis with history of rUTI after 1 year of the affected woman no longer being treated for rUTI and not meeting the criteria for the diagnosis of rUTI.

TABLE 1

TABLE 1

Back to Top | Article Outline

TREATMENT

Treatment options for rUTIs can be stratified by whether complicating features, such as abnormal genitourinary anatomy, immunosuppression, and chronic catheterization, are present. Most studies have focused on oral or parenteral antibiotic therapy, whereas data on intravesical and nonantibiotic treatments are limited.

Antibiotic therapy is typically used to treat active infections and prevent future infections; the treatment regimen, route, and duration will vary based on the clinical situation and should be individualized for each patient. Various antibiotic treatment strategies have been described for symptomatic patients with recurrent infections. These can be divided into treatment of an acute episode (provider prescribed or self-treatment) or prophylaxis (to prevent further episodes). Whenever possible, rUTI patients should have a culture sent before treatment. Empiric therapy can be initiated before urine culture results if clinically indicated (such as history of UTI-related sepsis or pyelonephritis). Antibiotic choice should be tailored to the individual patient and pathogens, community and patient resistance patterns, costs, drug availability, patient allergies, and patient tolerance/ability to comply.39 Providers should be familiar with the antibiotic-resistant patterns in their communities which is generally available via antibiograms through any clinical laboratory. Empiric regimens should be altered if necessary based on the urine culture results.

Back to Top | Article Outline

Treatment of UTI in Women With Recurrent UTI Without Complicating Features

Treatment recommendations for acute UTI in women with rUTI have been extrapolated from acute UTI treatment in women without rUTI. Conditional treatment and antibiotic therapy are the 2 treatment approaches with evidence of efficacy in uncomplicated, bacterial cystitis.40–44

With conditional treatment, either a nonsteroidal anti-inflammatory drug is used for symptomatic relief or patients are followed up without any form of treatment. Antibiotic therapy is only initiated if symptoms progress or do not resolve in a clinically reasonable time frame. Conditional treatment has not been studied in women older than 65 years or with rUTI. Several trials in women younger than 65 years have showed resolution rates of 20% to 47% without antibiotic treatment.40,41,45 However, one study documented a higher rate of pyelonephritis in the placebo group at 2% to 2.6%.45

Antibiotics are traditional first-line treatment of bacterial cystitis in women with rUTI.3 In women with rUTI, acute treatment can be initiated by a clinician or patient (self-treatment regimen) at the time of symptom onset.6 Most studies of acute UTI treatment were not performed in women with rUTI or other pelvic floor disorders.

Back to Top | Article Outline

Patient Considerations for Selection of Antimicrobial Agent

Allergies

Before prescribing antibiotics for a UTI, the clinician should review drug allergies and intolerances. Patients may have reported adverse drug reactions, side effects, and/or allergies to recommended first-line UTI antibiotics. Such patients can be further evaluated to determine whether they have drug side effect/adverse reaction vs a true allergic reaction (Table 2). Clinicians should not readminister an antibiotic in patients with previously severe reactions such as Stevens-Johnson syndrome unless essential for survival of the patient.48 Allergy desensitization may be considered for patients with challenging microbial resistance patterns.

TABLE 2

TABLE 2

Back to Top | Article Outline

Renal Function

Normal aging is associated with a decline in the estimated glomerular filtration rate and creatinine clearance (CrCl); this impacts the efficacy and toxicity of medications that are renally cleared, such as nitrofurantoin (recommended as first-line UTI therapy). Patients with decreased glomerular filtration rate are more likely to experience treatment failure due to reduced renal elimination.49 Nitrofurantoin is ineffective because of inadequate urine concentrations in patients with a CrCl of less than 30 mL/min. Prescribers should be familiar with antibiotic route of clearance and specific recommendations for renal dosing if indicated. Although more than 25% of individuals at least 65 years old have an estimated glomerular filtration rate of less than 60 mL/min, changes in microbial agent or dose based on age alone are not recommended.49,50

Nitrofurantoin has been underused based on decreased renal clearance, although updated guidelines support its use in previously restricted populations (CrCl <60 mL/min but >30 mL/min).49 The American Geriatrics Society 2015 Beers Criteria Update Expert Panel has updated its recommendation to decrease the CrCl threshold for using nitrofurantoin from 60 to 30 mL/min based on 2 retrospective studies.51

Back to Top | Article Outline

First-line Antimicrobial Agents

Few studies explore the optimal antibiotic choice in older women and women with rUTI. In the Infectious Disease Society of America guidelines for premenopausal women, 3 first-line antibiotics for UTI treatment are recommended: nitrofurantoin, trimethoprim-sulfamethoxazole (TMP-SMX) and fosfomycin39 (Table 3). Recommendations are extrapolated from these guidelines for use in rUTI, older women, and women with urogynecologic disorders.

TABLE 3

TABLE 3

Nitrofurantoin is bacteriostatic and therapeutically active only in the lower urinary tract. It is effective against E. coli and many gram-negative species with low levels of resistance.20,67 However, it is ineffective against other uropathogens including some Proteus species and some strains of Enterobacter and Klebsiella. 20 The duration of treatment is typically 7 to 10 days. A recent meta-analysis of studies of women ranging from 12 to 70 years old with variable eligibility criteria concluded that 5-day regimens are as effective,67 although this meta-analysis is not necessarily generalizable to women with rUTI. The 2010 “International clinical practice guidelines for the treatment of acute uncomplicated cystitis in women” recommends a 5-day regimen of 100 mg orally twice daily.39

Trimethoprim-sulfamethoxazole is a broad-spectrum antibiotic that covers gram-positive bacteria including methicillin-resistant Staphylococcus aureus and most gram-negative bacteria, excluding Pseudomonas. When there is greater than 20% local E. coli resistance to TMP-SMX, an alternative treatment should be given. Reported duration of TMP-SMX treatment has ranged from 3 to 14 days, with the 3-day course being found to have similar efficacy to 5- to 10-day regimens (see duration of therapy hereinafter).39

Fosfomycin tromethamine, the stable salt form of fosfomycin, is taken in a single dose which is highly concentrated in the urine resulting in urine levels that persist for 30 to 40 hours. Fosfomycin has activity against both gram-positive and gram-negative bacteria, including S. aureus, Enterococcus, Pseudomonas aeruginosa, and K. pneumoniae. 68–70 Fosfomycin has maintained relatively low levels of resistance, making it a drug of choice in infections with multidrug-resistant organisms.2,69,71–73 In addition, fosfomycin is an important therapeutic agent for treatment of extended-spectrum beta-lactamase (ESBL) E. coli UTI.

Back to Top | Article Outline

Second-line Antimicrobial Agents

When first-line medications are not available or cannot be prescribed because of patient allergies or intolerances or bacterial resistance, second-line antimicrobials, β-lactams, and fluoroquinolones can be used. β-Lactams (such as cefixime and cefpodoxime) have in vitro activity against most gram-negative uropathogens except Pseudomonas. Randomized trial evidence suggests that the effectiveness of 3-day cefpodoxime or TMP-SMX is comparable at 98.4% vs 100%.52 Generally, cephalosporins have a lower cure rate than did TMP-SMX and fluoroquinolones.20 Less well-studied β-lactams, like cephalexin, can also be used if first-line antibiotics are inappropriate for any reason.39

Although 3-day fluoroquinolones regimens (eg, ciprofloxacin and levofloxacin) are highly efficacious, they are not first-line agents because of increasing resistance, higher expense, and serious adverse events as described in a 2016 Food and Drug Administration warning.20,39,53,74

Back to Top | Article Outline

Not Recommended

Unless there is clear evidence of sensitivity to certain β-lactams, including amoxicillin and ampicillin, these antibiotics should rarely be used because of poor efficacy thought to be due in part to the lack of concentration in the urine.32,39

Back to Top | Article Outline

Duration of Short-course Therapy

The recommendation for the duration of acute bacterial cystitis treatment in women with rUTI is not evidence based and is extrapolated from women without rUTI; some experts use longer duration therapy in rUTI women. Although it did not specifically address women with rUTI, in a Cohrane systematic review and meta-analysis of 15 randomized controlled trials of 1644 elderly women comparing antibiotic duration for treatment of acute UTI, the authors found that the standard duration for short-course therapy (3–6 days), compared with 7 to 14 days, was sufficient treatment.75 The review also reported that single-dose therapy was associated with a higher rate of persistent UTI compared with short-course therapy (risk ratio [RR], 2.01;95% CI, 1.05–3.84). Of the 15 studies included in this review, only 2 studied fosfomycin.

This document supports the practice of using standard duration therapy and tailoring treatment as clinically necessary. The efficacy of 3-day regimens of TMP-SMX and fluoroquinolones has comparable effectiveness (79%–100% and 85%–98% cure rates) and is widely accepted for UTI treatment in the absence of complicating factors.52–57,76,77 These regimens are as effective for symptomatic relief as longer (5- to 10-day) regimens and have improved compliance, decreased costs, and lower rates of adverse reactions.20,39,78 The efficacy of 5 days of nitrofurantoin is comparable to 3 days of TMP-SMX.53,67,79 Five days of nitrofurantoin has better efficacy than a 3-day regimen.40,67,80,81 Table 4 displays drug-related adverse events.

TABLE 4

TABLE 4

Back to Top | Article Outline

Self-treatment With Antibiotics (Patient-initiated Therapy/Self-start Therapy)

Self-treatment can be associated with standing physician orders for urine culture before and, possibly, after treatment, to help maintain diagnostic clarity. For women who are traveling or otherwise unable to submit a urine specimen, rare episodes of self-treatment without culture are permissible. Compared with continuous prophylaxis, self-treatment is associated with a higher rate of infection (2.2 UTI per year vs 0.2 UTI per year).87 Self-treatment is an option for women (1) with the ability to reliably recognize UTI symptoms and start antibiotics, (2) who are not suitable for long-term prophylaxis, or (3) who do not wish to take long-term therapy.4,87–90

For self-treatment, clinicians prescribe the appropriate dose and duration of an antibiotic that will cover the most likely uropathogen based on the patient's history so that she can initiate treatment based on her symptoms. Women who use the self-treatment regimen should be capable of contacting their clinician if symptoms progress or fail to resolve within 48 hours. Table 3 displays the recommended self-treatment regimens. Antibiotic agents with minimal side effects are recommended to improve patient compliance and minimize adverse events and overtreatment.91,92

Fluorquinolones are not preferred agents for self-treatment regimens despite historical success, because of high cost, risk of resistance, and adverse event profile. We recommend use of other agents whenever possible.90

Back to Top | Article Outline

Recurrent UTI With Complicating Factors

Women with rUTI who have complicating factors, such as abnormal genitourinary anatomy, immunosuppression, and chronic catheterization, require additional vigilance in diagnosis and treatment because their bacterial isolates are more likely to be resistant to various antibiotics.19,33,93,94 When empiric therapy of an acute UTI with complicating factors is initiated, treatment should be reevaluated once urine culture and sensitivity results are available.95 The initial selection of empiric therapy should reflect the patient's individual uropathogen history, current treatment (eg, if currently on UTI suppression antibiotics), and response to prior therapy.33,94–104 If clinically reasonable, antimicrobial therapy should be delayed pending culture results and organism susceptibility so antimicrobial treatment can be targeted based on the uropathogen profile.95 Table 5 displays the recommended regimens for empiric therapy of UTI with complicating factors.

TABLE 5

TABLE 5

Back to Top | Article Outline

Pyelonephritis

Several otherwise useful UTI antibiotics are not recommended for acute pyelonephritis treatment, including nitrofurantoin and fosfomycin; TMP-SMX is not recommended for empiric treatment because of high rates of TMP-SMX resistance. Table 6 displays the recommended acute pyelonephritis treatment regimens. Empirically initiated antibiotics should be refined when the urine culture results are available.

TABLE 6

TABLE 6

Back to Top | Article Outline

Nonantibiotic Treatments and Nonoral/Nonparenteral Antibiotic Treatment

Ibuprofen—Initial Symptomatic Treatment

Ibuprofen may be used as an adjunct for symptoms of acute bacterial cystis. However, in women with rUTI, there is no evidence that ibuprofen should be used in lieu of an antibiotic (see previous discussion on conditional treatment).

Back to Top | Article Outline

Chinese Herbal Medicine

There is insufficient evidence to recommend Chinese herbal medicine (CHM) as rUTI treatment. The herbal products used in CHM (up to 10–15 herbs) have undergone in vitro studies showing biologic plausibility for rUTI treatment and clinical efficacy in studies. A 2015 Cochrane systematic review compared studies of CHM vs placebo, CHM vs antibiotics, and CHM plus antibiotics vs antibiotics alone.113 The systematic review was limited by a small number (7) of studies, small sample sizes, study design problems, and an overall high bias risk. Despite these limitations, the authors of the Cochrane review concluded that CHM may be beneficial for rUTI treatment during an acute episode (either as an independent or as an adjunct therapy) and may reduce rUTI for up to 6 months after treatment.

Back to Top | Article Outline

Intravesical Instillations

Antibiotic Bladder Irrigation

Antibiotic irrigation of the bladder for prophylaxis and/or treatment provides some potential advantages over oral and parenteral routes. These include direct drug delivery to the site of infection and bypass of gastrointestinal tract which avoids collateral consequences and side effects such as gastrointestinal upset.

Gentamicin has been the antibiotic most studied for bladder irrigation.114–116 There have been no randomized controlled trials performed to date, and all reports have been case series in individuals with complicated UTIs. Reports have included findings from in vitro, animal, and human studies. Bladder instillation regimens have included gentamicin solutions with concentrations ranging from 40–80 mg gentamicin with 50 mL normal saline; instillation volumes of 30 to 60 mL with at least a 1-hour or overnight dwell have been recommended. No elevated serum gentamicin levels were recorded, and all studies reported a meaningful reduction in UTIs while instillations were performed. Specialists may use this therapy in select patients, despite the lack of evidence from robust comparison studies. Limited current evidence supports the safety of gentamicin bladder instillations.

Back to Top | Article Outline

Colistin

Colistin is a polymyxin molecule that damages the lipopolysaccharide component of gram-negative bacteria, leading to increased membrane permeability and eventual cell death.117,118 Giua et al118 reported intravesical colistin use in 3 different critically ill patients with multidrug-resistant Acinetobacter. The intravesical treatment regimen was 100,000 UI colistin in 50 mL normal saline 3 times daily for 90 minutes for 7 days (2 patients) and 2 days (1 patient). All 3 patients were successfully treated. Although there are not sufficient data to recommend this treatment, it may be considered in a patient who has very limited treatment options.

Back to Top | Article Outline

PREVENTION

The goal of prophylaxis is to prevent or suppress subsequent infections. Although this is most commonly accomplished with antibiotics, alternative nonantibiotic options exist as well.

Back to Top | Article Outline

Antibiotic Prophylaxis

Both the European Association of Urology and the Society of Obstetricians and Gynaecologists of Canada recommend ensuring a negative urine culture before starting prophylactic antibiotics.32 Table 7 displays recommended postcoital and continuous antibiotic regimens. Postcoital prophylaxis should be offered to women who have UTIs temporally related to sexual intercourse. These women will take a single dose of an antimicrobial agent immediately after intercourse.6 Postcoital therapy decreased recurrence rates compared with placebo (0.3 vs 3.6 patient-years, P = 0.001) and was equally as efficacious as continuous daily therapy.44,119 This strategy has decreased costs, likely fewer medication side effects, and decreased risk of antibiotic resistance.4,119

TABLE 7

TABLE 7

With continuous prophylaxis, a patient takes a single, daily antibiotic dose.6 Compared with placebo, continuous prophylaxis decreases recurrences by up to 95%.20 The duration of these regimens ranges from 6 months (based on observations that UTIs tend to cluster and recur within 3 months) to at least 2 years; regimens have been extended to 5 years in some reports.96,102,113,131 A Cochrane systematic review of antibiotics for prevention of rUTI in nonpregnant women found that antibiotics given continuously for 6 to 12 months were considerably more effective than placebo in preventing rUTI (RR, 0.15; 95% CI, 0.08–0.28).44 Although low-dose prophylaxis with antibiotics may inhibit emergence of bacteria while on therapy, this inhibition may not extend when the antibiotic is discontinued.44,132 Several studies have found that 50% to 60% of women become reinfected within 3 months of discontinuing prophylaxis,102,113,133 perhaps due in part to intravesical bacterial persistence.134–136 Antibiotic prophylaxis may increase the risk of bacterial resistance. This document supports reevaluation of continuous antibiotic prophylaxis at 3 months to determine the efficacy and side effects. Antibiotic prophylaxis is rarely continued beyond 6 months, although it may have to be restarted if UTIs recur.

Back to Top | Article Outline

Estrogen

Vaginal estrogen should be used whenever possible in hypoestrogenic women with rUTI because it clearly decreases UTI recurrence. In a randomized, double-blind, placebo-controlled trial of 93 postmenopausal women assigned to topically applied intravaginal estriol cream (0.5 mg estriol in vaginal cream daily for 2 weeks, followed by twice weekly for 8 months) vs placebo, UTI incidence in the treatment group decreased significantly (0.5 vs 5.9 episodes per patient-year). In addition, after 1 month of treatment, lactobacillus appeared in 60% of the estrogen-treated group and none of the placebo group.137 In another multicenter randomized noncontrolled trial of 108 postmenopausal women with rUTI randomized to vaginal estrogen ring (2 mg estradiol, 1 ring for 12 weeks, for a total of 36 weeks), the vaginal estrogen ring significantly decreased UTI occurrences and prolonged the time to next occurrence.138 A Cochrane review of these studies indicated that vaginal cream may be more effective than the vaginal ring,88 although significant heterogeneity in these studies prohibited pooling of findings. A systematic review of vaginal estrogen treatment of vulvovaginal atrophy found moderate-quality evidence of decreased UTI risk in women with vaginal atrophy using vaginal estrogen.139 Studies comparing vaginal estrogen and antibiotics are inconclusive.88,140–142 Oral estrogen has not been shown to be effective and should not be used for rUTI prevention.

Back to Top | Article Outline

Methenamine Salts

A 2012 Cochrane review reported evidence that methenamine hippurate may be effective for preventing UTI, specifically when used for short-term prophylaxis. Methenamine salts are converted in the urine to ammonia and formaldehyde; formaldehyde is bacteriostatic and does not induce resistance. In addition, methenamine hippurate has an acceptable side-effect profile with low reported adverse events.143,144

Back to Top | Article Outline

Probiotics

There is no strong evidence supporting the role of probiotics in rUTI prevention. The main organisms used in probiotics come from lactobacilli strains, which produce antimicrobial compounds that inhibit pathogenic bacteria.145 A systematic review of 5 studies (n = 294) focusing only on premenopausal women with current UTI or history of UTI showed that using selected lactobacillus strains that achieve vaginal colonization could prevent rUTI.146 A larger Cochrane review that included 9 probiotic intervention studies (n = 735) with variable controls in healthy premenopausal and postmenopausal women found no significant reduction in rUTI in the probiotic group.147 However, findings from this study were inconclusive because the data were derived from small studies and inconsistent type and dose of probiotics. Robust, placebo-controlled studies are needed in patients with rUTI using optimal probiotic agents.

Back to Top | Article Outline

Cranberry

The preponderance of evidence does not support routine use of cranberry products in the care of women with rUTI. Proanthocynidins present in cranberries inhibit binding of type 1P-fimbriae of E. coli to uroepithelial cells. The studies included in systematic reviews of cranberry are limited by moderate heterogeneity, lack of consistency in dosing, and lack of information about proanthocynidin content. High dropout rates in cranberry juice groups suggest an adherence challenge. One systematic review of 10 trials (n = 1494) comparing cranberry products (juice, capsules, or tablets) to placebo or nonplacebo control in susceptible populations concluded that cranberry products reduced risk of UTI in various subpopulations including women with rUTI.148 A larger Cochrane review (n = 4473) of placebo and nonplacebo controlled trials using various cranberry products in men, women, and children with a history of at least 2 UTIs in the previous 12 months did not show a reduction in symptomatic UTI except in children.149 A more recent clinical trial of 185 elderly women randomized to cranberry capsules (72 mg, equivalent to 20 oz of cranberry juice) vs placebo showed no significant difference in bacteriuria plus pyuria; the study was not powered to detect differences in symptomatic UTI.28

Back to Top | Article Outline

D-Mannose and M4284

There is limited evidence supporting routine use of the simple sugar D-mannose in women with rUTI. D-Mannose, available over the counter, competitively inhibits adhesion of UPEC type 1 fimbria. D-Mannose decreases bacteria levels in animal UTI models.150 In a recent randomized clinical trial of 308 women with acute UTIs and history of rUTI in which women were first treated for their acute UTI and then randomized to 2 g of D-Mannose daily for 6 months, 50 mg of nitrofurantoin daily, or no prophylaxis, the rate of rUTI was 15%, 20%, and 60%, respectively. The D-mannose group had significantly fewer side effects and equal adherence.151

Back to Top | Article Outline

Ascorbic Acid (Vitamin C)

Although vitamin C has a theoretical effect based on acidification of urine, there is insufficient evidence to support its use for UTI prevention in women with rUTI. The 2 studies that have evaluated the effect of vitamin C had contradictory results.152,153

Back to Top | Article Outline

Nonantibiotic Intravesical Instillations

Nonantibiotic intravesical instillations, including hyaluronic acid and chondroitin sulfate, are promising; however, they do not yet have sufficient clinical evidence for use.154–157 The theory behind the use of hyaluronic acid and chondroitin sulfate is that damage to the glycosoaminoglycan layer of the urothelium is thought to play a key role in uncomplicated UTI.158

Back to Top | Article Outline

Immunoactive Prophylaxis

Immunostimulants and vaccinations are likely to play a future role in rUTI prevention, although there is insufficient evidence to recommend clinical use at this time. OM-89 is an oral immunostimulant extracted from 18 different heat-killed UPEC serotypes. In a systematic review of 4 studies (n = 891), there was a reduction in the mean number of UTI by approximately half in the treatment groups compared with placebo with a similar rate of adverse events. Urovac is a vaginal vaccination that contains 6 serotypes of UPEC, 1 strain of Proteus vulgaris, K. pneumoniae, Morganella morganii, and E. faecalis. Pooled results from 3 small studies suggest a slight reduction in rUTI (RR, 0.81; 95% CI, 0.68–0.96) but only in the groups that received booster therapy after the primary immunization.159

Back to Top | Article Outline

RECOMMENDATIONS

Specialists in FPMRS have a key role in the care of women with rUTI. As research on pathophysiology and best practices continues to inform our understanding of rUTI, these best practices will be updated. Key principles for current care are accuracy in diagnosis with thoughtful use of cystoscopy and imaging when needed, judicious use of appropriate antibiotics, and effective prevention strategies.

Readers are encouraged to read the entire best-practice document. The following lists highlight several key recommendations of these best practices:

Back to Top | Article Outline

Diagnosis

  • Thresholds for rUTI diagnosis are at least 2 in 6 months or at least 3 in 12 months.
  • Urine culture before initiating antibiotic therapy is recommended to document rUTI episodes and guide treatment.
  • Urine culture after appropriate therapy may help define distinct episodes.
Back to Top | Article Outline

Antibiotic Choice

Antibiotic choice should take into account specific patient factors (allergies, renal function), complicating factors, and uropathogen sensitivity.

For acute cystitis in women with rUTI,

  • nitrofurantoin is a key first-line agent;
  • fosfomycin is effective; clinician may need to request sensitivity testing;
  • TMP-SMX can also be used if resistance is less than 20% in the community; and
  • fluoroquinolones are not first-line treatment of acute cystitis without complicating factors.
Back to Top | Article Outline

Prevention

  • Postcoital antibiotic suppression is effective in women with coitally related rUTI.
  • Low-dose, daily antibiotic suppression (3–6 months) is effective in women with noncoitally related rUTI.
  • Effective nonantibiotic measures are
  • cessation of spermicides,
  • vaginal estrogen in hypoestrogenic women, and
  • methenamine.
Back to Top | Article Outline

REFERENCES

1. Haylen BT, Lee J, Husselbee S, et al. Recurrent urinary tract infections in women with symptoms of pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct 2009;20(7):837–842.
2. Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA 2014;311(8):844–854.
3. Gupta K, Trautner BW. Diagnosis and management of recurrent urinary tract infections in non-pregnant women. BMJ 2013;346:f3140.
4. Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J 2011;5(5):316–322.
5. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 2014;28(1):1–13.
6. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012;366(11):1028–1037.
7. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010;7(12):653–660.
8. Laupland KB, Ross T, Pitout JD, et al. Community-onset urinary tract infections: a population-based assessment. Infection 2007;35(3):150–153.
9. Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol 2000;151(12):1194–1205.
10. Suskind AM, Saigal CS, Hanley JM, et al. Incidence and management of uncomplicated recurrent urinary tract infections in a national sample of women in the United States. Urology 2016;90:50–55.
11. Hilt EE, McKinley K, Pearce MM, et al. Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. J Clin Microbiol 2014;52(3):871–876.
12. Amna MA, Chazan B, Raz R, et al. Risk factors for non–Escherichia coli community-acquired bacteriuria. Infection 2013;41(2):473–477.
13. Mulvey MA, Schilling JD, Martinez JJ, et al. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc Natl Acad Sci U S A 2000;97(16):8829–8835.
14. Silverman JA, Schreiber HL 4th, Hooton TM, et al. From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infections. Curr Urol Rep 2013;14(5):448–456.
15. Ejrnæs K, Stegger M, Reisner A, et al. Characteristics of Escherichia coli causing persistence or relapse of urinary tract infections: phylogenetic groups, virulence factors and biofilm formation. Virulence 2011;2(6):528–537.
16. Anderson GG, Palermo JJ, Schilling JD, et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 2003;301(5629):105–107.
17. Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci U S A 2006;103(38):14170–14175.
18. Gupta K, Stapleton AE, Hooton TM, et al. Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. J Infect Dis 1998;178(2):446–450.
19. Raz R, Gennesin Y, Wasser J, et al. Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis 2000;30(1):152–156.
20. Hooton TM. Recurrent urinary tract infection in women. Int J Antimicrob Agents 2001;17(4):259–268.
21. Scholes D, Hooton TM, Roberts PL, et al. Risk factors for recurrent urinary tract infection in young women. J Infect Dis 2000;182(4): 1177–1182.
22. Töz E, Kurt S, Sahin Ç, et al. Frequency of recurrent urinary tract infection in patients with pelvic organ prolapse. Res Rep Urol 2015;7:9–12.
23. Karram MM, Segal JL, Vassallo BJ, et al. Complications and untoward effects of the tension-free vaginal tape procedure. Obstet Gynecol 2003;101(5 Pt 1):929–932.
24. Nygaard I, Brubaker L, Chai TC, et al. Risk factors for urinary tract infection following incontinence surgery. Int Urogynecol J 2011;22(10):1255–1265.
25. Gehrich AP, Patzwald JR, Kern ME, et al. The incidence of early and recurrent urinary tract infections after midurethral sling operations. Mil Med 2014;179(11):1301–1306.
26. Ulrich D, Tammaa A, Hölbfer S, et al. Ten-year followup after tension-free vaginal tape-obturator procedure for stress urinary incontinence. J Urol 2016;196(4):1201–1206.
27. Bent S, Nallamothu BK, Simel DL, et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA 2002;287(20):2701–2710.
28. Juthani-Mehta M, Quagliarello V, Perrelli E, et al. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. J Am Geriatr Soc 2009;57(6):963–970.
29. Medina-Bombardó D, Seguí-Díaz M, Roca-Fusalba C, et al. What is the predictive value of urinary symptoms for diagnosing urinary tract infection in women? Fam Pract 2003;20(2):103–107.
30. Dune TJ, Price TK, Hilt EE, et al. Urinary symptoms and their associations with urinary tract infections in urogynecologic patients. Obstet Gynecol 2017;130(4):718–725.
31. Fitzgerald MP, Link CL, Litman HJ, et al. Beyond the lower urinary tract: the association of urologic and sexual symptoms with common illnesses. Eur Urol 2007;52(2):407–415.
32. Epp A, et al. Recurrent urinary tract infection. J Obstet Gynaecol Can 2010;32(11):1082–1101.
33. Grabe M, BM, Bjerklund-Johansen TE, et al. Guidelines on urological infections. EAU Guidelines edition presented at the 25th EAU Annual Congress, Barcelona, 2010 2010.
34. Cai T, Nesi G, Mazzoli S, et al. Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections. Clin Infect Dis 2015;61(11):1655–1661.
35. Ronald AR, Nicolle LE, Stamm E, et al. Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents 2001;17(4):343–348.
36. Baumgarten DA, Baumgartner BR. Imaging and radiologic management of upper urinary tract infections. Urol Clin North Am 1997;24(3):545–569.
37. Pagano MJ, Barbalat Y, Theofanides MC, et al. Diagnostic yield of cystoscopy in the evaluation of recurrent urinary tract infection in women. Neurourol Urodyn 2017;36(3):692–696.
38. Yu M, Jia HM, Zhou C, et al. Urinary and fecal metabonomics study of the protective effect of Chaihu-Shu-Gan-San on antibiotic-induced gut microbiota dysbiosis in rats. Sci Rep 2017;7:46551.
39. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52(5):e103–e120.
40. Christiaens TC, De Meyere M, Verschraegen G, et al. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 2002;52(482):729–734.
41. Gágyor I, Bleidorn J, Kochen MM, et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015;351:h6544.
42. Bleidorn J, Gágyor I, Kochen MM, et al. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? Results of a randomized controlled pilot trial. BMC Med 2010;8:30.
43. Bleidorn J, Hummers-Pradier E, Schmiemann G, et al. Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: follow-up of a randomised controlled trial. Ger Med Sci 2016;14:Doc01.
44. Albert X, Huertas I, Pereiró II, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004;(3):CD001209.
45. Ferry SA, Holm SE, Stenlund H, et al. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis 2004;36(4):296–301.
46. Vervloet D, Durham S. Adverse reactions to drugs. BMJ 1998;316(7143):1511–1514.
    47. Bhattacharya S. The facts about penicillin allergy: a review. J Adv Pharm Technol Res 2010;1(1):11–17.
      48. Boxer MB, Dykewicz MS, Patterson R, et al. The management of patients with sulfonamide allergy. N Engl Reg Allergy Proc 1988;9(3):219–223.
      49. Singh N, Gandhi S, McArthur E, et al. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. CMAJ 2015;187(9):648–656.
      50. Nicolle LE. Urinary tract infections in the older adult. Clin Geriatr Med 2016;32(3):523–538.
      51. Hoang P, Salbu RL. Updated nitrofurantoin recommendations in the elderly: a closer look at the evidence. Consult Pharm 2016;31(7):381–384.
      52. Kavatha D, Giamarellou H, Alexiou Z, et al. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrob Agents Chemother 2003;47(3):897–900.
      53. Iravani A, Klimberg I, Briefer C, et al. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother 1999;43(Suppl A):67–75.
      54. Arredondo-García JL, Figueroa-Damián R, Rosas A, et al. Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J Antimicrob Chemother 2004;54(4):840–843.
      55. Nicolle LE, Madsen KS, Debeeck GO, et al. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis 2002;34(7):487–492.
      56. Henry D, Ellison W, Sullivan J, et al. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. Antimicrob Agents Chemother 1998;42(9):2262–2266.
      57. Richard GA, Mathew CP, Kirstein JM, et al. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology 2002;59(3):334–339.
      58. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999;21(11):1864–1872.
        59. Minassian MA, Lewis DA, Chattopadhyay D, et al. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998;10(1):39–47.
          60. Naber KG, Allin DM, Clarysse L, et al. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. Int J Antimicrob Agents 2004;23(6):596–605.
            61. Fourcroy JL, Berner B, Chiang YK, et al. Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 2005;49(10):4137–4143.
              62. Henry DC Jr, Bettis RB, Riffer E, et al. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther 2002;24(12):2088–2104.
                63. Vogel T, Verreault R, Gourdeau M, et al. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. CMAJ 2004;170(4):469–473.
                  64. Auquer F, Cordón F, Gorina E, et al. Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women. Clin Microbiol Infect 2002;8(1):50–54.
                    65. Hooton TM, Scholes D, Gupta K, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 2005;293(8):949–955.
                      66. Leigh AP, Nemeth MA, Keyserling CH, et al. Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection. Clin Ther 2000;22(7):818–825.
                        67. Huttner A, Verhaegh EM, Harbarth S, et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother 2015;70(9):2456–2464.
                        68. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008;14(Suppl 1):198–202.
                        69. Seroy JT, Grim SA, Reid GE, et al. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis. J Antimicrob Chemother 2016;71(9):2563–2568.
                        70. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011;15(11):e732–e739.
                        71. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents 2003;22(Suppl 2):79–83.
                        72. Pullukcu H, Tasbakan M, Sipahi OR, et al. Fosfomycin in the treatment of extended spectrum beta-lactamase–producing Escherichia coli–related lower urinary tract infections. Int J Antimicrob Agents 2007;29(1):62–65.
                        73. Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010;65(9):1862–1877.
                        74. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. 2016–2017. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm. Accessed August 3, 2017.
                        75. Lutters M, Vogt-Ferrier NB. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst Rev 2008;(3):CD001535.
                        76. Hooton TM, Samadpour M. Is acute uncomplicated urinary tract infection a foodborne illness, and are animals the source? Clin Infect Dis 2005;40(2):258–259.
                        77. Zalmanovici Trestioreanu A, Green H, Paul M, et al. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2010;6(10):CD007182.
                        78. Milo G, Katchman EA, Paul M, et al. Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2005;(2):CD004682.
                        79. Gupta K, Hooton TM, Roberts PL, et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007;167(20):2207–2212.
                        80. Gupta K, Stamm WE. Pathogenesis and management of recurrent urinary tract infections in women. World J Urol 1999;17(6):415–420.
                        81. Hooton TM. A simplified approach to urinary tract infection. Hosp Pract (Off Ed) 1995;30(2):23–30.
                        82. Eiam-Ong S, Kurtzman NA, Sabatini S. Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int 1996;49(5):1372–1378.
                          83. Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. Ann Pharmacother 2013;47(12):1618–1626.
                            84. Iarikov D, Wassel R, Farley J, et al. Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database. Infect Dis Ther 2015;4(4):433–458.
                              85. Williams KJ, Hebblethwaite EM, Brown GW, et al. Cefuroxime axetil in the treatment of uncomplicated UTI: a comparison with cefaclor and augmentin. Drugs Exp Clin Res 1987;13(2):95–99.
                                86. Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA 2012;307(6):583–589.
                                  87. Wong ES, McKevitt M, Running K, et al. Management of recurrent urinary tract infections with patient-administered single-dose therapy. Ann Intern Med 1985;102(3):302–307.
                                  88. Perrotta C, Aznar M, Mejia R, et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008;(2): CD005131.
                                  89. Schaeffer AJ. Urinary tract infections in the elderly. Eur Urol 1991;19(Suppl 1):2–6.
                                  90. Gupta K, Hooton TM, Roberts PL, et al. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 2001;135(1):9–16.
                                  91. Engel JD, Schaeffer AJ. Evaluation of and antimicrobial therapy for recurrent urinary tract infections in women. Urol Clin North Am 1998;25(4):685–701. x.
                                  92. Nicolle LE. Update in adult urinary tract infection. Curr Infect Dis Rep 2011;13(6):552–560.
                                  93. Kunin CM. Antibiotic armageddon. Clin Infect Dis 1997;25(2):240–241.
                                  94. Nicolle LE. SHEA Long-Term-Care-Committee. Urinary tract infections in long-term-care facilities. Infect Control Hosp Epidemiol 2001;22(3):167–175.
                                  95. Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40(5):643–654.
                                  96. Nicolle LE, Ronald AR. Recurrent urinary tract infection in adult women: diagnosis and treatment. Infect Dis Clin North Am 1987;1(4):793–806.
                                  97. Abrutyn E, Mossey J, Berlin JA, et al. Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women? Ann Intern Med 1994;120(10):827–833.
                                  98. Mohler JL, Cowen DL, Flanigan RC. Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder. J Urol 1987;138(2):336–340.
                                  99. Harding GK, Nicolle LE, Ronald AR, et al. How long should catheter-acquired urinary tract infection in women be treated? A randomized controlled study. Ann Intern Med 1991;114(9): 713–719.
                                  100. Ouslander JG, Schapira M, Schnelle JF, et al. Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents? Ann Intern Med 1995;122(10):749–754.
                                  101. Boscia JA, Kobasa WD, Knight RA, et al. Therapy vs no therapy for bacteriuria in elderly ambulatory nonhospitalized women. JAMA 1987;257(8):1067–1071.
                                  102. Harding GK, Ronald AR, Nicolle LE, et al. Long-term antimicrobial prophylaxis for recurrent urinary tract infection in women. Rev Infect Dis 1982;4(2):438–443.
                                  103. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant gram-negative bacteria. J Antimicrob Chemother 2010;65(Suppl 3):iii25–iii33.
                                  104. Mazzulli T. Diagnosis and management of simple and complicated urinary tract infections (UTIs). Can J Urol 2012;19(Suppl 1):42–48.
                                  105. Klausner HA, Brown P, Peterson J, et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin 2007;23(11):2637–2645.
                                    106. Cronberg S, Banke S, Bergman B, et al. Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime. Scand J Infect Dis 2001;33(5):339–343.
                                      107. Wells WG, Woods GL, Jiang Q, et al. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother 2004;53(Suppl 2):ii67–ii74.
                                        108. Mouton YJ, Beuscart C. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group. J Antimicrob Chemother 1995;36(Suppl A):145–156.
                                          109. Naber KG, Llorens L, Kaniga K, et al. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009;53(9):3782–3792.
                                            110. Giamarellou H. Low-dosage cefepime as treatment for serious bacterial infections. J Antimicrob Chemother 1993;32(Suppl B):123–132.
                                              111. Naber KG, Savov O, Salmen HC. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents 2002;19(2):95–103.
                                                112. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000;283(12):1583–1590.
                                                  113. Flower A, Wang LQ, Lewith G, et al. Chinese herbal medicine for treating recurrent urinary tract infections in women. Cochrane Database Syst Rev 2015;(6): CD010446.
                                                  114. van Nieuwkoop C, den Exter PL, Elzevier HW, et al. Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterisation. Int J Antimicrob Agents 2010;36(6):485–490.
                                                  115. Abrams P, Hashim H, Tomson C, et al. The use of intravesical gentamicin to treat recurrent urinary tract infections in lower urinary tract dysfunction. Neurourol Urodyn 2017;36(8):2109–2116.
                                                  116. Wan J, Kozminski M, Wang SC, et al. Intravesical instillation of gentamicin sulfate: in vitro, rat, canine, and human studies. Urology 1994;43(4):531–536.
                                                  117. Newton BA. The properties and mode of action of the polymyxins. Bacteriol Rev 1956;20(1):14–27.
                                                  118. Giua R, Pedone C, Cortese L, et al. Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature. Infection 2014;42(1):199–202.
                                                  119. Stapleton A, Latham RH, Johnson C, et al. Postcoital antimicrobial prophylaxis for recurrent urinary tract infection. A randomized, double-blind, placebo-controlled trial. JAMA 1990;264(6):703–706.
                                                  120. Rudenko N, Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung 2005;55(7):420–427.
                                                    121. Stamm WE, Counts GW, Wagner KF, et al. Antimicrobial prophylaxis of recurrent urinary tract infections: a double-blind, placebo-controlled trial. Ann Intern Med 1980;92(6):770–775.
                                                      122. Brumfitt W, Hamilton-Miller JM. A comparative trial of low dose cefaclor and macrocrystalline nitrofurantoin in the prevention of recurrent urinary tract infection. Infection 1995;23(2):98–102.
                                                        123. Brumfitt W, Smith GW, Hamilton-Miller JM, et al. A clinical comparison between Macrodantin and trimethoprim for prophylaxis in women with recurrent urinary infections. J Antimicrob Chemother 1985;16(1):111–120.
                                                          124. Brumfitt W, Hamilton-Miller JM, Smith GW, et al. Comparative trial of norfloxacin and macrocrystalline nitrofurantoin (Macrodantin) in the prophylaxis of recurrent urinary tract infection in women. Q J Med 1991;81(294):811–820.
                                                            125. Brumfitt W, Hamilton-Miller JM, Havard CW, et al. Trimethoprim alone compared to co-trimoxazole in lower respiratory infections: pharmacokinetics and clinical effectiveness. Scand J Infect Dis 1985;17(1):99–105.
                                                              126. Seppanen J. Cinoxacin vs trimethoprim—safety and efficacy in the prophylaxis of uncomplicated urinary tract infections. Drugs Exp Clin Res 1988;14(10):669–671.
                                                                127. Pfau A, Sacks TG. Effective prophylaxis of recurrent urinary tract infections in premenopausal women by postcoital administration of cephalexin. J Urol 1989;142(5):1276–1278.
                                                                  128. Chew LD, Fihn SD. Recurrent cystitis in nonpregnant women. West J Med 1999;170(5):274–277.
                                                                    129. Martinez FC, Kindrachuk RW, Thomas E, et al. Effect of prophylactic, low dose cephalexin on fecal and vaginal bacteria. J Urol 1985;133(6):994–996.
                                                                      130. Lichtenberger P, Hooton TM. Antimicrobial prophylaxis in women with recurrent urinary tract infections. Int J Antimicrob Agents 2011;(Suppl 38):36–41.
                                                                        131. Franco AV. Recurrent urinary tract infections. Best Pract Res Clin Obstet Gynaecol 2005;19(6):861–873.
                                                                        132. Beerepoot MA, ter Riet G, Nys S, et al. Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Arch Intern Med 2011;171(14): 1270–1278.
                                                                        133. Car J, Sheikh A. Recurrent urinary tract infection in women. BMJ 2003;327(7425):1204.
                                                                        134. Mysorekar IU, Mulvey MA, Hultgren SJ, et al. Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli. J Biol Chem 2002;277(9):7412–7419.
                                                                        135. Justice SS, Hung C, Theriot JA, et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci U S A 2004;101(5):1333–1338.
                                                                        136. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 2001;69(7):4572–4579.
                                                                        137. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329(11):753–756.
                                                                        138. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999;180(5):1072–1079.
                                                                        139. Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014;124(6):1147–1156.
                                                                        140. Brown JS, Vittinghoff E, Kanaya AM, et al. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol 2001;98(6):1045–1052.
                                                                        141. Cardozo L, Benness C, Abbott D. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. Br J Obstet Gynaecol 1998;105(4):403–407.
                                                                        142. Raz R, Colodner R, Rohana Y, et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin Infect Dis 2003;36(11): 1362–1368.
                                                                        143. Lee BS, Bhuta T, Simpson JM, et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev 2012;10:CD003265.
                                                                        144. Hickling DR, Nitti VW. Management of recurrent urinary tract infections in healthy adult women. Rev Urol 2013;15(2):41–48.
                                                                        145. Mastromarino P, Vitali B, Mosca L. Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol 2013;36(3):229–238.
                                                                        146. Grin PM, Kowalewska PM, Alhazzan W, et al. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can J Urol 2013;20(1):6607–6614.
                                                                        147. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev 2015;(12):CD008772.
                                                                        148. Wang CH, Fang CC, Chen NC, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012;172(13): 988–996.
                                                                        149. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2012;10:CD001321.
                                                                        150. Michaels EK, Chmiel JS, Plotkin BJ, et al. Effect of D-mannose and D-glucose on Escherichia coli bacteriuria in rats. Urol Res 1983;11(2):97–102.
                                                                        151. Kranjcec B, Papes D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol 2014;32(1):79–84.
                                                                        152. Castelló T, Girona L, Gómez MR, et al. The possible value of ascorbic acid as a prophylactic agent for urinary tract infection. Spinal Cord 1996;34(10):592–593.
                                                                        153. Ochoa-Brust GJ, Fernández AR, Villanueva-Ruiz GJ, et al. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy. Acta Obstet Gynecol Scand 2007;86(7):783–787.
                                                                        154. Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol 2011;59(4):645–651.
                                                                        155. Constantinides C, Manousakas T, Nikolopoulos P, et al. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int 2004;93(9):1262–1266.
                                                                        156. De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J 2012;23(12):1707–1713.
                                                                        157. Lipovac M, Kurz C, Reithmayr F, et al. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet 2007;96(3):192–195.
                                                                        158. Parsons CL. Pathogenesis of urinary tract infections. Bacterial adherence, bladder defense mechanisms. Urol Clin North Am 1986;13(4):563–568.
                                                                        159. Beerepoot MA, Geerlings SE, van Haarst EP, et al. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol 2013;190(6):1981–1989.
                                                                        Keywords:

                                                                        UTI; recurrent UTI; urinary tract infections

                                                                        Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.